Genezen, a contract development and manufacturing organization (CDMO) specializing in gene and cell therapy, has announced the appointment of Dr. Susan D’Costa as Chief Technology Officer (CTO) and Dr. Nicole O’Brien as Chief Commercial Officer (CCO). Dr. D’Costa’s extensive experience in molecular virology, particularly in AAV manufacturing, will contribute to the growth of Genezen’s AAV business unit. She has held leadership positions at various companies in the gene and cell therapy field, including Florida Biologix, Brammer Bio, Thermo Fisher Scientific, and Alcyone Therapeutics. Dr. O’Brien brings valuable expertise in designing and implementing manufacturing programs for gene and cell therapies, gained from her previous roles at Thermo Fisher Scientific, Brammer Bio, and FujiFilm Diosynth.
Steve Favaloro, President and CEO of Genezen, expressed excitement about the addition of these renowned experts to the leadership team, highlighting their exceptional knowledge and experience. Their appointments will further accelerate Genezen’s growth, following the establishment of a new cGMP multi-vector production facility in Fishers, Indiana in 2022. Guided by its strong leadership team, Genezen aims to become a leader in development and manufacturing services for retroviral, AAV, and lentiviral vectors.
Dr. D’Costa expressed her enthusiasm for the role, emphasizing her passion for building gene therapy capabilities and Genezen’s potential to develop new AAV vector production capabilities. Dr. O’Brien shared her excitement about joining Genezen during this pivotal growth phase, where she will lead the commercial strategy and execution, leveraging the company’s technical and operational expertise to meet clients’ manufacturing needs.
Genezen, with a decade of experience in the gene and cell therapy market, is a leading supplier of retroviral vectors, lentiviral vectors, and AAV. The company prioritizes scientific excellence and invests in scalable manufacturing processes and advanced technologies. With strategic locations connected to advanced modality hubs, Genezen is well-positioned to serve the rapidly evolving gene and cell therapy field. For more information, please visit genezen.com.
